CSLLY: CSL insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
6 institutions reported holding $601K of CSL on Form 13F (7 the quarter before). 0 opened a new position and 1 sold out. Shares held by institutions: -49%.
| Largest holders | Shares | Value |
|---|---|---|
| RHUMBLINE ADVISERS | 23,969 | $481K |
| GAMMA Investing LLC | 3,694 | $74K |
| Salomon & Ludwin, LLC | 1,993 | $41K |
| PNC Financial Services Group, Inc. | 220 | $4K |
| IMA Advisory Services, Inc. | 29 | $582 |
| First Command Advisory Services, Inc. | 6 | $120 |
Clinical trial readouts
4 Phase 2 or 3 trials by Csl with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2026-09-23 | Recombinant single-chain factor VIII (rVIII-SingleChain) | Congenital Hemophilia A | Phase 3 | 62 | Completed | NCT06738485 |
| 2027-04-06 (est.) | BE1116 | Complex Cardiovascular Surgery With Cardiopulmonary Bypass | Phase 3 | 200 | Recruiting | NCT07094087 |
| 2027-06-30 (est.) | CSL511 Fibrinogen concentrate (human) | Acquired Fibrinogen Deficiency | Phase 3 | 90 | Recruiting | NCT06617897 |
| 2027-10-22 (est.) | CSL889 | Sickle Cell Disease Vaso-occlusive Crisis | Phase 2 | 70 | Recruiting | NCT06699849 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.